Genprex Inc. signs exclusive license to additional diabetes technology with University of Pittsburgh
Genprex, Inc. (@genprex) / Twitter
Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes - Genprex
GPX-002 and GPX-003 - Genprex
In the News: Aldevron Partner, Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy
Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh
Genprex Inc unveils groundbreaking data from primate study on its novel gene therapy to treat Type 1 diabetes at International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2023), in Berlin
Genprex enters license agreement with University of Pittsburgh to support diabetes program | BioWorld
Genprex sees newly licensed diabetes gene therapy as an 'opportunity we couldn't pass up' - Genprex
Genprex - Reprogramming the course of cancer and diabetes and diabetes
Genprex's Diabetes Gene Therapy Presented at ADA21 by UPMC - Genprex
Genprex (NASDAQ:GNPX) is targeting large patient populations with unmet needs in diabetes and cancer - YouTube
Genprex Inc targets non-small cell lung cancer and diabetes via gene therapy
Genprex, Inc. - Read more about the potentially curative gene therapy for diabetes: http://bit.ly/39u2Aqm | Facebook
Genprex veröffentlicht innovative Daten aus einer nicht-menschlichen Primaten Studie zur Bewertung einer neuartigen Gentherapie zur Behandlung von Typ-1-Diabetes auf der 16. internationalen Jahreskonf | Media - EQS News
Genprex Announces Groundbreaking Data From Non-Human Primate Study Evaluating Novel Gene Therapy To Treat Type 1 Diabetes At 16th Annual International Conference On Advanced Technologies & Treatment For Diabetes 2023 | Business Manchester
Videos Archive - Genprex
Genprex Inc. boosts its diabetes gene therapy program with the license of additional technology from the University of Pittsburgh
Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes at 16th Annual International Conference on Advanced Technologies & Treatment for Diabetes 2023 - Genprex
Pitt licenses technology for potential diabetes treatment | Pittsburgh Post-Gazette
Taking A Gander At Genprex (NASDAQ:GNPX) | Seeking Alpha
Genprex Inc announces $4M direct offering with single, healthcare-focused institutional investor
Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer | Business Wire
Genprex Inc has an exciting gene therapy platform, Dawson James notes as it assigns Buy rating in initial coverage
Genprex Announces Groundbreaking Data From Non-Human Primate Study Evaluating Novel Gene Therapy To Treat Type 1 Diabetes At 16th Annual International Conference On Advanced Technologies & Treatment For Diabetes 2023 | Business Manchester
Genprex, Inc. (@genprex) / Twitter
